Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|February 20, 2006
Pharmacists can tame new strain of C. difficile
The results of a new study indicated that a previously uncommon strain of Clostridium difficile has become more resistant to fluoroquinolones.
Advertisement
Advertisement
Related to this article
As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.
Data found reduced cardiovascular risk with hormone therapy, particularly among Black women and those starting treatment within 10 years of menopause.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
Pennsylvania has become the center of the outbreak as cases exceed 775 alongside conflicting mortality reports.
The LATA trial found long-acting cabotegravir–rilpivirine is better than daily oral therapy at keeping adolescents virologically suppressed.
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
Mark Garofoli, PharmD, BCGP, CPE, CTTS, explains how to guide patients past crowded combination products, uncertain decongestants, and hidden risks in OTC aisles.
Advertisement
Advertisement
Trending on Drug Topics
1
Injectable HIV Treatment Beats Daily Pills in Adolescent Trial
2
FDA Approves Onswik Weekly Insulin for Adults With T2D
3
Study Finds Reduced Cardiovascular Risk With Hormone Therapy Initiation
4
Conflicting Measles Reports Perpetuate as Cases Continue to Rise
5